Bioventus Inc. (BVS) Insider Trading

Last 12 months

Insiders sold $313k and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Director Michelle McMurry-Heath sold $131k on Nov 7, 2025, 24% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2024.

Net open-market

−$313k

0 buys · 3 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Aug 2024

Aug 19, 2024

Get an email when BVS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Mar 11	Michelle McMurry-Heath Director	SoldNo plan	12,000	$8.79	$105k	21%	Form 4
Dec 4, 2025	Guy P Nohra Director	SoldNo plan	10,000	$7.57	$76k	7.9%	Form 4
Nov 7, 2025	Michelle McMurry-Heath Director	SoldNo plan	17,701	$7.42	$131k	24%	Form 4
Apr 11, 2025	Mark Leonard Singleton SVP & CFO	Sold10b5-1 plan	3,875	$7.57	$29k	2.7%	Form 4
Apr 11, 2025	Anthony D'Adamio SVP & General Counsel	Sold10b5-1 plan	2,958	$7.57	$22k	2.2%	Form 4
Apr 11, 2025	Katrina J Church SVP & Chief Compliance Officer	Sold10b5-1 plan	1,283	$7.57	$10k	2.3%	Form 4
Mar 24, 2025	Mark Leonard Singleton SVP & CFO	Sold10b5-1 plan	5,479	$9.79	$54k	4.0%	Form 4
Mar 17, 2025	Katrina J Church SVP & Chief Compliance Officer	Sold10b5-1 plan	1,018	$9.75	$10k	1.9%	Form 4
Mar 17, 2025	Anthony D'Adamio SVP & General Counsel	Sold10b5-1 plan	2,615	$9.75	$25k	2.1%	Form 4
Feb 18, 2025	Mark Leonard Singleton SVP & CFO	Sold10b5-1 plan	6,498	$10.19	$66k	5.2%	Form 4
Feb 18, 2025	Anthony D'Adamio SVP & General Counsel	Sold10b5-1 plan	4,380	$10.19	$45k	3.6%	Form 4
Feb 18, 2025	Katrina J Church SVP & Chief Compliance Officer	Sold10b5-1 plan	1,537	$10.19	$16k	3.0%	Form 4
Jan 13, 2025	Robert E Claypoole President and CEO	Sold10b5-1 plan	28,786	$9.10	$262k	31%	Form 4
Dec 23, 2024	Mark Leonard Singleton SVP & CFO	Sold10b5-1 plan	10,733	$10.53	$113k	9.3%	Form 4
Dec 23, 2024	Katrina J Church SVP & Chief Compliance Officer	Sold10b5-1 plan	2,535	$10.53	$27k	5.1%	Form 4
Dec 23, 2024	Anthony D'Adamio SVP & General Counsel	Sold10b5-1 plan	5,848	$10.53	$62k	5.1%	Form 4

Mar 11No plan
Michelle McMurry-Heath
Director · sold 12,000 at $8.79
$105k
21% of stake
Dec 4, 2025No plan
Guy P Nohra
Director · sold 10,000 at $7.57
$76k
7.9% of stake
Nov 7, 2025No plan
Michelle McMurry-Heath
Director · sold 17,701 at $7.42
$131k
24% of stake
Apr 11, 202510b5-1 plan
Mark Leonard Singleton
SVP & CFO · sold 3,875 at $7.57
$29k
2.7% of stake
Apr 11, 202510b5-1 plan
Anthony D'Adamio
SVP & General Counsel · sold 2,958 at $7.57
$22k
2.2% of stake
Apr 11, 202510b5-1 plan
Katrina J Church
SVP & Chief Compliance Officer · sold 1,283 at $7.57
$10k
2.3% of stake
Mar 24, 202510b5-1 plan
Mark Leonard Singleton
SVP & CFO · sold 5,479 at $9.79
$54k
4.0% of stake
Mar 17, 202510b5-1 plan
Katrina J Church
SVP & Chief Compliance Officer · sold 1,018 at $9.75
$10k
1.9% of stake
Mar 17, 202510b5-1 plan
Anthony D'Adamio
SVP & General Counsel · sold 2,615 at $9.75
$25k
2.1% of stake
Feb 18, 202510b5-1 plan
Mark Leonard Singleton
SVP & CFO · sold 6,498 at $10.19
$66k
5.2% of stake
Feb 18, 202510b5-1 plan
Anthony D'Adamio
SVP & General Counsel · sold 4,380 at $10.19
$45k
3.6% of stake
Feb 18, 202510b5-1 plan
Katrina J Church
SVP & Chief Compliance Officer · sold 1,537 at $10.19
$16k
3.0% of stake
Jan 13, 202510b5-1 plan
Robert E Claypoole
President and CEO · sold 28,786 at $9.10
$262k
31% of stake
Dec 23, 202410b5-1 plan
Mark Leonard Singleton
SVP & CFO · sold 10,733 at $10.53
$113k
9.3% of stake
Dec 23, 202410b5-1 plan
Katrina J Church
SVP & Chief Compliance Officer · sold 2,535 at $10.53
$27k
5.1% of stake
Dec 23, 202410b5-1 plan
Anthony D'Adamio
SVP & General Counsel · sold 5,848 at $10.53
$62k
5.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BVS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

ATRCAtriCure, Inc.

GKOSGlaukos Corporation

UFPTUFP Technologies Inc.

AORTArtivion Inc.

NVCRNovoCure Ltd.

ARAYAccuray Incorporated

MDXGMiMedx Group, Inc.

TCMDTactile Systems Technology Inc.

Spot a number that looks wrong? Check it in BVS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BVS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.